A double-blind, placebo-controlled, Phase 3 trial in patients heterozygous for the F508del mutation and a specific mutation.

31 окт. 2019 г. · In conclusion, this 24-week, phase 3 trial involving 403 patients with cystic fibrosis confirmed the efficacy of triple-combination CFTR ...

People taking TRIKAFTA reported a significant 20.1-point average increase in CF respiratory symptom score compared with placebo at 4 weeks.

Trial 3 was a 2-part study: Part A was a pharmacokinetic and safety study, and Part B evaluated safety, tolerability, efficacy, and pharmacokinetics.

This study will look at the effectiveness of Trikafta®, a drug intended to help CFTR function closer to normal. This study is for people ages 12 and older ...

31 окт. 2019 г. · Patients received twice daily TRIKAFTA or placebo for 24 weeks. The primary efficacy endpoint was change in lung function as determined by ...

3 июл. 2021 г. · The effectiveness of Trikafta, seen in clinical trials, outperforms currently available therapies in terms of lung function, quality of life ...

Both studies met primary and all key secondary endpoints demonstrating significant improvements in lung function and other measures of the disease -.

26 авг. 2024 г. · In this trial, we evaluate whether ETI improves CFTR function, measured by sweat chloride and other clinical outcomes, in people with cystic fibrosis and CFTR ...

21 июл. 2024 г. · The study will evaluate response of patients with NCFB to ETI, and test usefulness of iPSC-derived airway epithelial monolayers as a novel in vitro technology.